Search results
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 5 days agoA Phase 3 study is already underway with the initial results expected later this decade. But at...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks via Yahoo Finance· 4 days agoLagevrio (molnupiravir) generated sales of $350 million in the first quarter, down 5% year over...
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 7 days agoInvestor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine,...
Merck (MRK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 4 days agoTurning...grew 24% to $6.9 billion driven by increased uptake from earlier-stage cancers and continued strong demand from metastatic indications....
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 5 days agoNew York, USA, April 24, 2024 (GLOBE NEWSWIRE) -- HDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the growth of the HDAC inhibitors market is expected
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Morningstar· 5 days agoThe NDA is supported by results from JUPITER-02, a randomized, double...
Merck highlights progress on HIV, hypertension, cervical cancer drugs
WFMZ Eastern Pennsylvania and Western New Jersey· 4 days agoMerck got off to an excellent start in the first quarter of 2024. Wall Street met the news with...
Nisa Investment Advisors LLC Has $29,000 Position in Janux Therapeutics, Inc. (NASDAQ:JANX)
ETF DAILY NEWS· 7 days agoNisa Investment Advisors LLC lifted its position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 10,740.0% during the fourth quarter, according to its most recent 13F filing with ...
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
Char-Koosta News· 5 days agoSAN FRANCISCO and SUZHOU, China, April 24, 2024 /PRNewswire/ -- Innovent Biologics, Inc....
Mirae Asset Global Investments Co. Ltd. Trims Stock Position in Iovance Biotherapeutics, Inc....
ETF DAILY NEWS· 6 days agoMirae Asset Global Investments Co. Ltd. trimmed its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 3.4% during the fourth quarter, according to its ...